

Resource Summary Report

Generated by [RRID](#) on Sep 7, 2026

JY

RRID:CVCL_0108

Type: Cell Line

Proper Citation

RRID:CVCL_0108

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0108

Proper Citation: RRID:CVCL_0108

Description: Cell line JY is a Transformed cell line with a species of origin Homo sapiens (Human)

Sex: Male

Defining Citation: [PMID:6294325](#), [PMID:6417007](#), [PMID:7523570](#), [PMID:22238296](#), [PMID:23619976](#), [PMID:25576301](#), [PMID:25960936](#), [PMID:28360230](#), [PMID:29242379](#), [PMID:30844424](#), [PMID:34925382](#)

Comments: Virology: Contains an integrated xenotropic MuLV-related virus (XMRV) Bxv-1 (PubMed=22238296)., Population: Caucasian; Amish., Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel.

Category: Transformed cell line

Organism: Homo sapiens (Human)

Name: JY

Synonyms: JY-S

Cross References: BTO:BTO_0003044, CLO:CLO_0037202, ChEMBL-Cells:ChEMBL3308061, ChEMBL-Targets:ChEMBL613833, dbMHC:48917, ECACC:94022533, IHW:IHW09287, IPD-IMGT/HLA:10882, PRIDE:PXD000394, PRIDE:PXD001872, PRIDE:PXD006939, PRIDE:PXD028633, PRIDE:PXD028874, PubChem_Cell_line:CVCL_0108, Wikidata:Q6109290

ID: CVCL_0108

Record Creation Time: 20220427T220654+0000

Ratings and Alerts

No rating or validation information has been found for JY.

No alerts have been found for JY.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 5 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Chen Y, et al. (2026) Benchmarking Software for DDA-PASEF Immunopeptidomics. Molecular & cellular proteomics : MCP, 25(4), 101492.

Ghaffari S, et al. (2026) A fully human pan VL9 HLA-E TCRm antibody enables functional dissection of HLA-E biology and checkpoint signaling. iScience, 29(5), 115669.

Gomez-Zepeda D, et al. (2024) Thunder-DDA-PASEF enables high-coverage immunopeptidomics and is boosted by MS2Rescore with MS2PIP timsTOF fragmentation prediction model. Nature communications, 15(1), 2288.

King LA, et al. (2024) Leveraging V α 9V β 2 T cells against prostate cancer through a VHH-based PSMA-V β 2 bispecific T cell engager. iScience, 27(12), 111289.

Lameris R, et al. (2023) A bispecific T cell engager recruits both type 1 NKT and V α 9V β 2-T cells for the treatment of CD1d-expressing hematological malignancies. Cell reports. Medicine, 4(3), 100961.